17,230 Shares in USANA Health Sciences, Inc. (NYSE:USNA) Purchased by Marshall Wace LLP

Marshall Wace LLP purchased a new position in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 17,230 shares of the company's stock, valued at approximately $618,000. Marshall Wace LLP owned 0.09% of USANA Health Sciences as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. R Squared Ltd bought a new position in shares of USANA Health Sciences in the 4th quarter worth approximately $28,000. KLP Kapitalforvaltning AS purchased a new stake in USANA Health Sciences in the fourth quarter worth $83,000. Quantbot Technologies LP bought a new position in USANA Health Sciences in the fourth quarter worth $132,000. Meeder Asset Management Inc. purchased a new position in USANA Health Sciences during the fourth quarter valued at $143,000. Finally, Amundi boosted its holdings in shares of USANA Health Sciences by 85.3% during the 4th quarter. Amundi now owns 4,872 shares of the company's stock valued at $170,000 after buying an additional 2,243 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company's stock.

USANA Health Sciences Stock Up 0.6 %

Shares of NYSE USNA traded up $0.17 during midday trading on Thursday, hitting $28.55. The stock had a trading volume of 19,002 shares, compared to its average volume of 126,208. The company has a market cap of $538.45 million, a P/E ratio of 10.09, a PEG ratio of 0.93 and a beta of 0.60. USANA Health Sciences, Inc. has a 52 week low of $23.10 and a 52 week high of $49.78. The business's 50 day moving average is $27.37 and its 200-day moving average is $32.79.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of $0.70 by $0.03. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The company had revenue of $249.54 million for the quarter, compared to the consensus estimate of $243.08 million. During the same quarter in the prior year, the firm earned $0.86 earnings per share. As a group, analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other USANA Health Sciences news, insider David Mulham Mulham sold 3,234 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $32.98, for a total transaction of $106,657.32. Following the completion of the sale, the insider now owns 12,775 shares of the company's stock, valued at approximately $421,319.50. The trade was a 20.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Joshua Foukas sold 5,732 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total transaction of $186,519.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 16,594 shares of company stock valued at $520,384. 0.63% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on USNA shares. StockNews.com lowered shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. DA Davidson dropped their price target on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research report on Thursday, February 27th. Finally, Sidoti lowered USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, February 18th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.